Clinical trials
catalyst calendar across sponsors →Studies where RLYB is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional · 1 observational · 1 with posted results
Held by 5 tracked-famous managers (CITADEL ADVISORS LLC, VIKING GLOBAL INVESTORS LP, RENAISSANCE TECHNOLOGIES LLC, JANE STREET GROUP, LLC, TWO SIGMA INVESTMENTS, LP) · FINRA short interest 2.1 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of RLYB116 in Healthy ParticipantsNCT06797375Number of participants with treatment related adverse events as defined by CTCAE 5.0.Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: RLYB116 for Injection | Hematologic Diseases, Autoimmune Diseases | 16 | 2026-02-09actual | 2026-02-27 |
| Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a AlloimmunizationNCT06435845results2026-03-06Number of Participants With Treatment Related Adverse Events as Defined by CTCAE 5.0Open-label · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: This study was terminated early by the sponsor due to insufficient drug exposure to achieve the intended therapeutic effect. | Drug: Anti-(integrin beta-3) human monoclonal antibody | Fetal and Neonatal Alloimmune Thrombocytopenia | 1 | 2025-10-01actual | 2026-03-06 |
| Study to Assess the Occurrence of HPA-1a Alloimmunization in Women With Higher Risk for Fetal and Neonatal Alloimmune ThrombocytopeniaNCT05345561observationalNumber of participants with higher FNAIT risk characterized by race and ethnicityStudy Protocol ↗ · Statistical Analysis Plan ↗ | — | Completed | Other: Clinical data collection | Fetal and Neonatal Alloimmune Thrombocytopenia | 14,390 | 2025-01-31actual | 2026-03-06 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19